Thomsen Henrik S, Almèn Torsten, Morcos Sameh K
Department of Diagnostic Radiology 54E2, Copenhagen University Hospital at Herlev, Herlev Ringvej 75, 2730 Herlev, Denmark.
Eur Radiol. 2002 Oct;12(10):2600-5. doi: 10.1007/s00330-002-1628-3. Epub 2002 Aug 16.
Recently, it has been suggested that gadolinium-based contrast media could be used for radiological examinations in patients with significant renal impairment, previous severe generalized reaction to iodinated contrast media or thyroid disease about to undergo radioactive iodine treatment; however, the indications for and risks of using gadolinium agents in this way are not well known; hence, the Contrast Media Safety Committee of The European Society of Urogenital Radiology reviewed the literature to issue a position paper on this subject. A comprehensive literature review was performed and the resulting report was discussed at the Ninth European Symposium on Urogenital Radiology in Genoa, Italy, June 2002. Review of the literature indicates that according to experimental data on animals gadolinium-based contrast media have more nephrotoxic potential than iodinated contrast media in equivalent X-ray attenuating doses; therefore, gadolinium-based contrast media should not replace iodinated contrast media in patients with renal insufficiency for radiographic examinations. For patients with previous severe generalized reactions to iodinated contrast media, and in patients about to undergo thyroid treatment with radioactive iodine gadolinium-based contrast media in approved intravenous doses, up to 0.3 mmol/kg body weight will not give diagnostic radiographic information in most cases. Gadolinium-based contrast media are not approved for radiographic examinations.
最近,有人提出钆基造影剂可用于有严重肾功能损害、既往对碘化造影剂有严重全身性反应或即将接受放射性碘治疗的甲状腺疾病患者的放射学检查;然而,以这种方式使用钆剂的适应症和风险尚不清楚;因此,欧洲泌尿生殖放射学会造影剂安全委员会对文献进行了回顾,以发表关于该主题的立场文件。进行了全面的文献回顾,并在2002年6月于意大利热那亚举行的第九届欧洲泌尿生殖放射学研讨会上讨论了所得报告。文献回顾表明,根据动物实验数据,在等效的X射线衰减剂量下,钆基造影剂比碘化造影剂具有更大的肾毒性潜力;因此,在肾功能不全患者的影像学检查中,钆基造影剂不应替代碘化造影剂。对于既往对碘化造影剂有严重全身性反应的患者,以及即将接受放射性碘甲状腺治疗的患者,批准的静脉注射剂量高达0.3 mmol/kg体重的钆基造影剂在大多数情况下不会提供诊断性影像学信息。钆基造影剂未被批准用于影像学检查。